ARCHIVES

Drug Development: ODAC Discussion May Offer Clues For Sponsors of Cytostatic Drugs

This article is from The Cancer Letter archive.

Vol. 25 No. 24 | June 16, 1999

Download PDF Visit The Full Archive

Related Articles

Afinitor and Sutent Approved For Pancreatic Neuroendocrine Tumors

May 27, 2011

Varmus’s 2016 Bypass Budget Seeks “Modest” Increase of $823 Million

December 5, 2014

FDA News: Agency Abandons Plan To Merge Two Offices, Citing Delay Request From Employees’ Union

June 19, 1998

ONS, ASCO, AACR Growth Surge Continues; Flex Political Muscles During DC Meetings

June 8, 1990

Owens Becomes President, NCCR

June 21, 1996

Cech To Step Down At HHMI In 2009.

April 18, 2008